Adrenomedullin (ADM), a ubiquitous vasoactive peptide, has been the target of a multitude of studies concerning its effect on the vascular tone. The present work aims at clarifying a series of its interactions with the renin-angiotensin system.
Introduction
One of the newly-discovered vasoactive peptides, with local autocrine and paracrine hormonal properties is adrenomedullin (ADM). Initially discovered in human phaeochromocytoma, 1 ADM was later identified in many other tissues and organs, beginning with the adrenal glands, kidney, heart, lung and brain and ending with vascular smooth muscle and vascular endothelium. 2 On a structural level, it has been established that ADM is a 52-aminoacid peptide, similar to the Calcitonin Gene Related Peptide (CGRP), with the genetic expression located on chromosome 11 in man. 3 Its precursor, preproadrenomedullin, an 185 aminoacid peptide, generates both ADM and the 20amino-acid pro-adrenomedullin peptide (PADMP), which has similar but weaker vascular actions. 4 During the decade since the discovery of ADM, a large amount of experimental data has been gathered describing its ubiquitous distribution and multifunctional regulating properties. 5 Thus, it has been made clear that, at the vascular level, ADM has vasodilator effects, mediated by the stimulation of nitric oxide (NO) synthesis. 6 These effects are also due to the inhibition of endothelin formation and muscle cell proliferation at the vascular level. 7 Relaxation by ADM occurs along the whole vascular tree, in both the systemic and pulmonary circulations. 8 Unlike arteries, in which the basal tone decreases in presence of ADM before and after removal of vascular endothelium, venous relaxation is endothelium-dependent. 9 The vascular myorelaxing effects, including in those in the coronary and pulmonary circulations, are more obvious in small vessels than in large ones, 10 and are accompanied both by a cardiac inotropic action and by a decrease in cathecholamine, aldosterone and vasopressin synthesis, together with diuresis and natriuresis. 11 At the cerebral level, ADM can be found in the supraoptic and paraventricular nuclei of the hypothalamus and induces the inhibition of adrenocorticotrophic hormone (ACTH) and vasopressin secretion, accompanied by an increase in oxytocin release. 12 These multiple actions of ADM are due to its affinity for a transmembrane receptor with a higher sensitivity for ADM than for CGRP, 13 coupled with a G protein and adenylate cyclase which generates cAMP as a second messenger. 14 Other mechanisms may also be involved, such as the activation of hyperpolarising potassium channels by ADM, 15 the NO-cGMP pathways 16 or presynaptic inhibition of adrenergic neurotransmission. 17 In resistance arteries,ADM induces dilatory effects, as has been described in the mesenteric bed 18 and in cerebral vessels. 15 Plasma concentrations of ADM are increased in patients with congestive heart failure, myocardial infarction, high blood pressure and renal disease, as a compensatory phenomenon, counteracting local and general haemodynamic imbalances induced by these diseases. 19 Significant increases were observed also in pregnancy, septic shock, hypoxia and oxidative stress. 20 On the contrary, maximal exercise reduces ADM concentration in athletes. 21 Concerning the relationship between ADM and the renin-angiotensin system, data in the literature show both the stimulation by ADM of renin secretion 22 and the inhibition of the aldosteronereleasing action of angiotensin II (Ang II). 19, 23, 24 In turn, Ang II stimulates ADM secretion, in common with endothelin or inflammatory cytokines. 25 Since the influence of ADM upon the effects of vasoactive angiotensins has been less thoroughly investigated, 26 we have initiated a comparative study in this respect.We examined the inhibitory effects of ADM upon the contraction induced by Ang II in the rat thoracic aorta and small mesenteric arteries.
Materials and methods
Experiments were done in vitro, on vascular rings from the thoracic aorta and from the second order branches of the superior mesenteric arteries of adult male Wistar rats (80-250 g) killed by decapitation and exsanguination.All the experiments are in accordance with UK guidelines and the European Communities Council Directive 609 of 24 November 1986 and all the procedures are approved by the Committee on Animal Use for Research at the University of Medicine and Pharmacy 'Gr T Popa' Iasi. All drugs were purchased from Sigma-Aldrich Co.The results are presented as illustrative individual traces and percentile graphs (mean±SEM; n=10 in all series).The statistical significance was analysed using t-test and ANOVA.
Experiments using thoracic aorta
The thoracic aorta was excised and placed in physiological saline solution (PSS) containing (mM): NaCl 118; KCl 4.7; CaCl 2 2.52; MgSO 4 1.64; NaHCO 3 24.88; KH 2 PO 4 1.18; glucose 5.55. The connective tissue was then removed and the vessel was cut into 3-4 mm wide rings.
Where appropriate, endothelium was removed by gentle rubbing with moist filter paper. The presence of a functional endothelium was checked pharmacologically (using carbachol) and by direct microscopy. Intact or endotheliumremoved aortic rings were mounted in organ baths containing 4 ml PSS, bubbled with 95% O 2 and 5% CO 2 at 37°C. For the recording of the vascular smooth muscle contractions, we used isometric force transducers connected to a computer data acquisition system. Preparations were equilibrated for 60 minutes, under a resting tension of 100 mN. The rings were then precontracted with phenylephrine (10 -7 -10 -6 M) and K + (40-70 mM) and treated with carbachol (10 -6 M) for the release of vasorelaxing endothelial NO. 27 The absolute magnitude of contraction was 175±25 mN for phenylephrine (10 -6 M) and 85±15 mN for Ang II (10 -6 M).
The vascular effects of ADM (10 -10 -10 -6 M) were studied in intact and endothelium-removed rings, either in resting conditions or precontracted by phenylephrine or potassium. Its influence on the pressor action of Ang II (10 -7 -10 -5 M) was evaluated based upon changes in the reactivity of rings pretreated with ADM.This interaction was further examined in the presence of L-NAME (10 -6 M, NOsynthase blocker) and methylene-blue (MB, 10 -5 M); which has been used as specific guanylate cyclase (GC) inhibitor in functional studies in various vascular preparations, including the rat aorta and mesenteric arteries. 28 In order to avoid tachyphylaxis, the administration of Ang II was repeated only after more than 60 minutes.
Experiments using rat mesenteric small arteries
Male Wistar rats (180-220 g) were decapitated and proximal jejunal loops were excised and immersed in PSS (see above). Second order branches of the mesenteric artery (~2 mm length, 0.1 mm diameter) were obtained by microdissection (ocular x 32, objective x 1, illumination by reflection). When required, the endothelium was removed by repeatedly passing a rough hair through the lumen of the vascular fragment. The rings were mounted on stainless steel wires in a horizontal small vessel myograph (Dual 500, JP Trading, DK), connected to a PC through an AD converter (Duo, World Precision Instruments, USA). The PSS used was kept at 37°C and vigorously bubbled with a mixture of 95% O 2 and 5% CO 2 (pH 7.2-7.4). The rings were stretched stepwise up to an optimal tension 29 and equilibrated for 60 minutes (PSS replaced every 15 minutes). The relaxing effect of ADM is expressed as residual active force, normalised (%) to the reference value represented by the plateau (15 minutes) of the precontraction induced by K + 40 mM (K40), phenylephrine 0.01 mM (FEN), or PGF2α 0.01 mM (PGF). ADM was given as pre-treatment for contractions induced by 10 -6 M Ang II (ANG), where the reference value is represented by the peak active force induced in the absence of ADM. L-NAME 10 -6 M and MB 10 -5 M were administered as pre-treatment (10 minutes) and maintained thereafter.
Results

Influence of ADM on pressor effects of phenylephrine, angiotenisn II, and K + in thoracic aorta rings
In a first series of experiments, we tested the myorelaxing effects of ADM in thoracic aorta rings precontracted with phenylephrine or K + . In both situations,ADM induced the well-known decrease of vascular tone, both in intact and de-endothelised aortic rings (Figure 1) .
The vasodilating effects of ADM in aortic rings precontracted with phenylephrine were not significantly diminished by L-NAME pre-treatment (95±5%). Unlike the precontracted rings, the basal tone of the rings incubated with ADM did not show any significant changes. In contrast with precontraction experiments, pre-treatment of the intact rings with various doses of ADM did not influence ( Figure 2 ) the sub-sequent contractions induced by phenylephrine (98.3±1.7%) and K + (85±15%) in absence or presence of L-NAME.
On the contrary, vasoconstriction induced by Ang II was more strongly inhibited by ADM in intact preparations than in de-endothelised ones (Figure 3) .
The dose-effect relationship of ADM on Ang II contractions is shown in Figure 4 . IC50 for deendothelised preparations was 1.2 nM and IC50 for endothelised preparations was calculated at 0.2 nM.
Specific inhibition of NO synthase by L-NAME significantly decreased the myorelaxing action of ADM on the vasoconstricting effects of Ang II ( Figure 5 ). In turn, L-NAME potentiated the Ang II vasoconstricting effects, as shown previously. 30 The same inhibition of the ADM myorelaxing action on the Ang II-induced vasoconstriction was achieved both in normal or denuded rings, pretreated with MB as specific GC inhibitor. 28, 31 These results are in favour of the inhibitory properties of ADM on the pressor effects of Ang II, with the involvement of NO-cGMP as an inhibiting modulator system.
Influence of ADM on pressor effects of phenylephrine, angiotensin II, and K + in small mesenteric arteries
Using fragments from second-order branches of the superior mesenteric artery pre-contracted with phenylephrine or K + , we have observed that ADM dose-dependently induces the same myorelaxing effects. (Figure 6 ).
The vasoconstricting effects of Ang II were strongly inhibited by ADM, in both normal and denuded fragments, suggesting a direct mechanism involved in these effects. In favour of this direct mechanism is also the elimination of the inhibitory effects of ADM by the blockade of soluble GC with MB ( Figure 7) . The vasoconstricting effects of Ang II (44.2±11.7 mN) were not altered (p>0.1) in the presence of L-NAME (46±13.7 mN) or MB (40.2±7.8 mN). Unlike the effects observed in the aortic rings (as conductance vessels), which are endothelium-dependent, the inhibitory actions of ADM on Ang II-induced vasoconstriction in the small mesenteric arteries is potentiated by L-NAME.
Overall, the presented results suggest a different mechanism of the inhibitory influence of ADM on Ang II-induced vasoconstriction in conductance and resistance vessels.
Discussion
These results confirm previously reported data concerning both the vascular myorelaxing properties of ADM in small and large vessels 8, 18 and its inhibiting effects upon the vasoconstrictor action of Ang II. 26 Regarding the mechanism of the inhibitory modulation by ADM of the vasopressor effects of Ang II, our research brings new experimental evidence in favour of the involvement of the NOcyclic GMP couple in the myorelaxing and vasodilator actions of ADM. Conductance and resistance vessels behave differently in this respect, as discussed below.
In agreement with some data from the literature, 6, 16 the vasodilating effects of ADM in precontracted rat aortic rings are endothelium-dependent, relying on the involvement of the endothelial NO-cGMP pathway.
The inhibition of NO-synthase with L-NAME significantly reduced the inhibitory action of ADM on the Ang II-induced vasoconstriction, more intensely in intact thoracic aortic rings than in deendothelised ones, as shown in Figures 3 and 4 .
On the contrary, the second-degree mesenteric artery fragments showed myorelaxing effects with ADM, both in the presence and the absence of vascular endothelium.
Opposite effects were also obtained with second-order mesenteric arteries pretreated with L-NAME, showing potentiation by L-NAME of the inhibitory action of ADM on the vasoconstricting effects of Ang II. The complete inhibition of the vasopressor effects of Ang II by ADM in the presence of L-NAME points to a different modulatory role of NO in these small arteries.
As an inhibiting modulator of vascular reactivity, NO seems to have greater importance in conductance arteries, with a higher content of endothelial NO, than in resistance arteries. In the latter, L-NAME was not able to diminish the inhibitory properties of ADM, but even showed a significant potentiation. Unlike the case of L-NAME, inhibition of GC with MB diminished the inhibiting actions of ADM on the vasoconstrictor effects of Ang II in both conductance and resistance arteries. Thus, the roles of NO and cyclic GMP in ADM effects, including the particular aspects in small arteries, 10, 15, 18 deserve further investigation. 
